Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …

Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant
benefits to non-small cell lung cancer patients with EGFR mutations, which represent a …

Simple Summary Ovarian cancer (OC) is the most lethal gynecological malignancy with a
five-year survival rate of 47%, followed by cervical cancer (66%), and uterine cancer (81%) …

The emergence of anti–cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), anti–programmed
cell death 1 ligand (anti–PD-1), and anti–PD-L1 antibodies as immune checkpoint inhibitors …

Immunotherapy is changing the Head and Neck Squamous Cell Carcinoma (HNSCC)
landscape and improving outcomes for patients with recurrent or metastatic HNSCC. A …

Background The tumor microenvironment (TME) impacts the therapeutic efficacy of immune
checkpoint inhibitors (ICIs). No liquid biomarkers are available to evaluate TME …

Background The definition of hyperprogressive disease (HPD) is controversial in the
literature and has not been widely described in melanoma. The aim of this study was to …

Immunotherapy, an antitumor therapy designed to activate antitumor immune responses to
eliminate tumor cells, has been deeply studied and widely applied in recent years. Immune …